Pharmaceutical, Bioprocessing and Biomedical Technologies
Our Pharmaceutical, Bioprocessing and Biomedical Technologies researchers specialise in the conception, design and scale-up of manufacturing processes for the conversion of chemical and biological materials into pharmaceuticals and medical devices.
Our Pharmaceutical, Bioprocessing and Biomedical Technologies researchers are particularly focused on developing, enhancing and understanding:
- micro-plasma-made nanoparticles and nanocoatings for bionano medical applications (antibacterial, biomarking)
- molecular design of engineered proteins as drug or vaccine candidates
- tissue engineering and regenerative medicines for degenerated organs or cells, especially in cartilage
- drug and gene delivery into cancer cells
- game-changing concepts for continuous-flow process chemistries and systems for (end-to-end) API and bio synthesis
- process-automated PAT monitoring of pharma-bio continuous-flow chemistries with online sampling
- in-situ real-time pharma-bio process monitoring through plasma and laser diagnostics technologies.
Our Pharmaceutical, Bioprocessing and Biomedical Technologies researchers aim to:
- enhance pharmaceutical industry manufacturing processes
- lay the fundamental foundations to revolutionise protein-based nanomedicine, making production more efficient and rapid, and the medicine more effective
- develop novel therapeutic technologies to tackle community health challenges, such as cartilage regeneration and cancer therapy.
Our Pharmaceutical, Bioprocessing and Biomedical Technologies research is of direct benefit and relevance to the pharmaceutical and health industries. Through our research, we aim to:
- develop the process chemistry spearhead of next generation (FDA, 2026) continuous manufacturing of pharmaceuticals
- develop new chemistry processes, as well as special chemistries, for innovation in food and agriculture
- develop novel nanomedicine for targeted cancer treatment and infectious disease
- translate design to medical needs by developing high throughput bioprocesses for engineered nanomedicine production
- develop novel therapeutic technologies to tackle healthcare challenges, such as cartilage regeneration and cancer therapy.
Our research has had significant real-world impact. We are:
- recognised by the US Food and Drug Administration as one of the world’s top three contributors to pharmaceutical manufacturing innovation
- frequently the first source consulted and cited concerning flow chemistry and microreactor industrial applications
- internationally recognised for our significant contribution in developing innovative vaccine purification processes and quality control
- engaging in quality-by-design (QbD) bioprocess screening with biopharmaceutical companies (for biosimilar development).
Additionally, our researchers have developed hydrogels that are now being incorporated with cardiac stem cells for heart repair procedures—a novel treatment approach that has already produced promising results in mice and pigs.
We advise on, and lead, projects relating to:
- protein-based macromolecule design, expression, purification and formulation
- bioprocess development, from mammalian cell culture (fermentation) to downstream primary recovery and purification
- bioprocess and pharmaceutical process modelling and simulation.
We have also recently begun consulting in pharmaceutical process chemistry and analytics.
We have expertise across a wide range of areas. Many of our researchers are available to assist with research project supervision for Master of Philosophy and Doctor of Philosophy students.
|Professor Volker Hessel|
|Professor Robert Falconer|
|Associate Professor Jingxiu Bi|
We collaborate with various industry and government organisations, including:
- Australian Institute of Bioengineering and Nanotechnology, University of Queensland
- Helmholtz Centre for Infection Research, Braunschweig (Germany)
- Institute of Process Engineering, Chinese Academy of Sciences, Beijing (China)
- University of New South Wales